Nelarabine Injection Now Available

Share Facebook icon Twitter icon Linkedin icon

Meitheal Pharmaceuticals (Meitheal) is pleased to announce that we have launched Nelarabine Injection, 250 mg per 50 mL, in a single-dose vial.

Meitheal will offer Nelarabine Injection in a carton of 6 vials.

ABOUT NELARABINE INJECTION

Nelarabine Injection is a nucleoside metabolic Inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens link.

Learn more about Nelarabine Injection.

This Website Uses Cookies

This website uses cookies to help give you the best experience when you visit. By clicking “Accept Cookies,” you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and help us make improvements to our site. You can read more about our use of cookies in our Privacy Policy.

Manage Consent Preferences

Always Active

Necessary cookies enable core functionality such as security and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

These cookies are set to provide quantitative measures of website visitors. Information collected with these cookies is used in operations to measure website performance. With the usage of these cookies we are able to count visits and traffic sources to improve our site. The data is collected in a way that does not directly identify anyone.
Accept all cookies Confirm my choices